Findings

What do systematic reviews say?

6 questions · 6 findings · 3 reviews · Vascular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 1 · 16.7%Very low 1 · 16.7%Low 3 · 50%Moderate 1 · 16.7%High 0 · 0%

IVIg vs acetylsalicylic acid (ASA)

Mortality (all‐cause) · people undergoing initial treatment for KD

1 finding from 1 review

Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation

All‐cause mortality(7‐day) · people with intermediate‐risk (submassive) APE

1 finding from 1 review

Catheter‐directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 59 participants
GRADE not reported

Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation

All‐cause mortality (90‐day) · people with intermediate‐risk (submassive) APE

It is very uncertain whether ultrasound‐assisted catheter‐directed thrombolysis plus standard… changes all‐cause mortality (90‐day) compared with standard intravenous heparinisation (very low certainty).

1 finding from 1 review

Catheter‐directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute… 2022 · Cochrane Headline outcomes only
OR 0.31 [0.01, 7.96]
1 study · 59 participants
Very low

IVIg vs different infusion regimens of IVIG

Mortality (all‐cause) (up to 7 weeks) · people undergoing initial treatment for KD

1 finding from 1 review

Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 549 participants
Moderate

IVIg vs prednisolone

Mortality (all‐cause) (up to 30 days) · people undergoing initial treatment for KD

1 finding from 1 review

Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 90 participants
Low

Subcutaneous unfractionated heparin vs unfractionated heparin

All‐cause mortality (5 days to 12 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (5 days to 12 months) compared with intravenous unfractionated heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism 2017 · Cochrane Headline outcomes only
OR 1.74 [0.67, 4.51]
8 studies · 972 participants
Low